Why are so few patients taking the new sickle cell drugs? :

A new drug runs into red tape from insurers, a long history of bias against sickle-cell patients, and debate over data.

Related Keywords

Philadelphia , Pennsylvania , United States , Georgia , New Jersey , South Carolina , University Of South Carolina , Illinois , Chapel Hill , Chicago , Americans , Elizabeth Rendon , Lee Klafczynski , Janice Haney Carr , Ilena Harvey , Alan Anderson , Ashley Valentine , Lakiea Bailey , Kim Smith Whitley , Lewis Hsu , Dominique Goodson , Kenneth Ataga , Julie Kanter , Adult Sickle Cell Program , Sickle Cell Consortium Bailey , Sickle Cell Consortium , University Of Illinois Chicago , Drug Administration , Sickle Cell Foundation Of Georgia , University Of Alabama At Birmingham , Pfizer , Duke University , Anthony , Global Blood Therapeutics , Sick Cells , Therapy Sickle Cell , Janice Haney , Sickle Cell Foundation , Alexandra Power Hays , Sickle Cell Disease , Tennessee Health Science , Sickle Cell , Jane Little , For Pfizer ,